荷兰女性口咽部沙眼衣原体常规普遍检测与选择性或偶然检测的比较:一项回顾性队列研究
该研究利用2008年1月1日至2017年12月31日荷兰全部性传播感染门诊的女性监测数据,比较口咽部沙眼衣原体常规普遍检测、选择性检测与偶然检测的阳性率。结果显示常规普遍检测组阳性率低于选择性检测组(2.4% vs 2.9%,p<0.0001),偶然检测组阳性率更高(4.1%,p<0.0001);作者认为不存在最优检测方案,相对较低的仅口咽部感染率(0.5%)不支持常规普遍检测。
要点
- 常规普遍检测组口咽部沙眼衣原体阳性率2.4%,低于选择性检测组的2.9%(p<0.0001)。
- 按外推估算,选择性检测将漏诊估计总感染中的64.4%(95%CI 63.5-65.3)。
- 仅口咽部沙眼衣原体比例在常规普遍检测女性(22.9%)与选择性检测女性(20.4%)间差异2.5%(95%CI -0.3至5.3;p=0.07)。
核心结论
- 作者认为口咽部沙眼衣原体不存在最优检测方案,仅检测部分高危女性即可发现大多数感染;仅口咽部感染率相对较低(0.5%)且临床与公共卫生影响可能有限,不支持常规普遍检测。
研究设计与样本
- 回顾性队列研究,使用2008年1月1日至2017年12月31日荷兰所有地区性传播感染门诊就诊女性的监测数据,纳入至少接受一次沙眼衣原体检测的541945次就诊(占550615次咨询的98.4%,含重复就诊)。
主要发现
- 常规普遍检测组口咽部沙眼衣原体阳性率为2.4%(1081/45774,95%CI 2.2-2.5),低于选择性检测组的2.9%(3473/121262,95%CI 2.8-3.0;p<0.0001)。
- 偶然检测组阳性率为4.1%(44/1073,95%CI 3.1-5.5),高于常规普遍检测组(p<0.0001)。
- 按外推估算,选择性检测将漏诊估计总感染中的64.4%(95%CI 63.5-65.3;6363/9879)。
- 仅口咽部沙眼衣原体比例在常规普遍检测女性为22.9%、选择性检测女性为20.4%,差异2.5%(95%CI -0.3至5.3;p=0.07)。
- 以口咽部沙眼衣原体危险因素作为检测指征时,19459名女性中15484名(79.6%)需接受检测,可检出494例感染中的398例(80.6%)。
关键数值与推荐
- 常规普遍检测定义为每门诊年度口咽部检测比例>85%,选择性检测为5-85%,偶然检测为<5%。
- 作者结论指出相对较低的仅口咽部沙眼衣原体感染率(0.5%)和可能有限的临床与公共卫生影响不支持常规普遍检测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharyngeal Chlamydia trachomatis in women might contribute to autoinoculation and transmission to sexual partners. Data for effectiveness of different testing practices for pharyngeal C trachomatis are scarce. We therefore aimed to assess the prevalence of pharyngeal C trachomatis, determinants, and effectiveness of different testing practices in women. METHODS: We did a retrospective cohort study, in which surveillance data for all women visiting sexually transmitted infection clinics in all regions in the Netherlands between Jan 1, 2008, and Dec 31, 2017, were used. We collected consultation-level data and individual-level data from 2016 onwards for sociodemographic characteristics, sexual behaviour in the past 6 months, self-reported symptoms, and STI diagnoses. The primary outcome was the positivity rate of pharyngeal C trachomatis infection compared between routine universal testing (>85% tested pharyngeally per clinic year), selective testing (5-85% tested pharyngeally per clinic year), and incidental testing (<5% pharyngeally tested per clinic year). We calculated the number of missed infections by extrapolating the positivity rate assessed by routine universal testing to all selectively tested women. We used multivariable generalised estimating equations logistic regression analyses to assess independent risk factors for pharyngeal C trachomatis and used the assessed risk factors as testing indicators for comparing alternative testing scenarios. FINDINGS: Between Jan 1, 2008, and Dec 31, 2017, a total of 550 615 consultations with at least one C trachomatis test was recorded, of which 541 945 (98·4%) consultations (including repeat visits) were included in this analysis. Pharyngeal C trachomatis positivity was lower in the routine universal testing group than in the selective testing group (1081 [2·4%; 95% CI 2·2-2·5] of 45 774 vs 3473 [2·9%; 2·8-3·0] of 121 262; p<0·0001). The positivity rate was also higher among consultations done in the incidental testing group (44 [4·1%; 95% CI 3·1-5·5] of 1073; p<0·0001) than in the routine universal testing group. Based on extrapolation, selective testing would have hypothetically missed 64·4% (95% CI 63·5-65·3; 6363 of 9879) of the estimated total of C trachomatis infections. The proportion of pharyngeal-only C trachomatis was comparable between routinely universally tested women (22·9%) and selectively tested women (20·4%), resulting in a difference of 2·5% (95% CI -0·3 to 5·3; p=0·07). When using risk factors for pharyngeal C trachomatis as testing indicators, 15 484 (79·6%) of 19 459 women would be tested to detect 398 (80·6%) of 494 infections. INTERPRETATION: No optimal testing scenario was available for pharyngeal C trachomatis, in which only a selection of high-risk women needs to be tested to find most pharyngeal C trachomatis infections. The relative low prevalence of pharyngeal-only C trachomatis (0·5%) and probably limited clinical and public health effect do not provide support for routine universal testing. FUNDING: Public Health Service South Limburg.
引用
- Evers YJ, van Liere GAFS, Dukers-Muijrers NHTM, et al. Routine universal testing versus selective or incidental testing for oropharyngeal Chlamydia trachomatis in women in the Netherlands: a retrospective cohort study. Lancet Infect Dis. 2021. PMID: 34919829. doi:10.1016/S1473-3099(21)00465-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。